Related Experiment Video
Updated: Aug 6, 2026
09:56
Implantation of Combined Telemetric ECG and Blood Pressure Transmitters to Determine Spontaneous Baroreflex Sensitivity in Conscious Mice
Published on: February 14, 2021
Aldosterone impairs baroreflex sensitivity in healthy adults
Kevin D Monahan1, Urs A Leuenberger, Chester A Ray
1Penn State Heart and Vascular Institute, The Milton S. Hershey Medical Center, Campus Box H047, 500 University Dr., Hershey, PA 17033-2390, USA. kmonahan@psu.edu
American Journal of Physiology. Heart and Circulatory Physiology
|August 22, 2006
Summary
Aldosterone impairs the body's ability to regulate blood pressure through the baroreflex in humans. This study demonstrates that aldosterone reduces both cardiovagal baroreflex sensitivity and sympathetic baroreflex sensitivity.
Area of Science:
- Cardiovascular physiology
- Endocrinology
- Autonomic neuroscience
Background:
- Animal studies suggest aldosterone negatively impacts baroreceptor/baroreflex responses.
- Baroreflexes are crucial for short-term blood pressure regulation.
- Aldosterone's effect on human baroreflex function requires direct investigation.
Purpose of the Study:
- To test if aldosterone impairs baroreflex control of cardiac period (cardiovagal baroreflex sensitivity) and muscle sympathetic nerve activity (sympathetic baroreflex sensitivity) in humans.
- To investigate the direct impact of aldosterone on autonomic cardiovascular regulation.
Main Methods:
- A randomized controlled study involving 26 healthy young adults.
- The modified Oxford technique was used to assess baroreflex sensitivity before and after infusions.
- Participants received either aldosterone or saline infusion, with blood pressure, heart rate, and muscle sympathetic nerve activity measured.
Main Results:
- Aldosterone infusion significantly increased serum aldosterone levels.
- Cardiovagal baroreflex sensitivity decreased by approximately 18% after aldosterone infusion.
- Sympathetic baroreflex sensitivity also significantly decreased following aldosterone administration.
- Control group (saline infusion) showed no changes in baroreflex sensitivity.
Conclusions:
- Aldosterone directly impairs baroreflex function in humans, affecting both cardiovagal and sympathetic components.
- These findings suggest aldosterone plays a significant role in modulating baroreflex control of blood pressure.
- Understanding aldosterone's impact on baroreflexes is critical for managing cardiovascular health.
Related Concept Videos
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...